Issue 3/2012

  • Are released GM mosquitos safe?

    In this issue:

    • Novartis poised to enter HCV market with Enanta compound
    • Norway to use sequencing data in the country’s healthcare system
    • Oxford Nanopore shakes up Next-Gen sequencing market
    • BIO-Europe Spring: Antibodies – Unlocking new markets
    • Spain leads EU project for iPSCs in cell replacement therapies
    • Bioton joins forces with Actavis to develop biosimilar insulins
    • European Commission presents 2020 roadmap to bioeconomy

Volume 2014

Volume 2013

Volume 2012

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/magazine/ebsin/2012/3/pos/1.html?sort=asc&cHash=2aa63e7a3c47f54d547eeaaa494e591b

Kurszettel

Alle Kurse

TOP

  • MEDIGENE4.64 EUR7.16%
  • FORMYCON16.89 EUR4.07%
  • BIOFRONTERA1.99 EUR3.65%

FLOP

  • HBM102.00 CHF-2.86%
  • SYNGENTA327.00 CHF-2.15%
  • STRATEC BIOMEDICAL45.12 EUR-2.10%

TOP

  • WILEX3.17 EUR47.4%
  • EVOLVA1.70 CHF18.9%
  • MEDIGENE4.64 EUR16.0%

FLOP

  • MOLOGEN5.25 EUR-12.5%
  • SANTHERA98.45 CHF-10.2%
  • 4SC0.77 EUR-9.4%

TOP

  • SANTHERA98.45 CHF2417.9%
  • WILEX3.17 EUR395.3%
  • FORMYCON16.89 EUR119.4%

FLOP

  • CYTOS0.37 CHF-86.9%
  • MOLOGEN5.25 EUR-56.0%
  • PAION2.10 EUR-52.5%

No liability assumed, Date: 03.03.2015